welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
The Role of Family Functioning in Promoting Adaptation in Siblings of Individuals With Duchenne Muscular Dystrophy (DMD)
study id #: NCT01386515
condition: Genetic Disease, Communication
Background: We want to learn more about the relationship between the way families function and how children adapt to having a sibling with Duchenne muscular dystrophy (DMD). What we learn will help us design better interventions for families. Objective: – To learn more about how families with an individual with DMD function. – To learn how siblings adapt in families with an individual with DMD. Eligibility: – One parent and one child, age 13-18, from a family where another child has DMD. – The parent and the child must be able to read and write English. Design: – One parent from each family will complete a survey about how family members communicate and relate with each other. The parent will also answer questions about the behavior of the child without DMD. This survey will take you about 40 minutes to complete. – One child from each family, either a boy or a girl, will also complete a survey. This survey asks about how he/she views him/herself. It also asks about how he/she interacts with peers and family members and how he/she behaves. The survey also asks how satisfied he/she is with how his/her family functions. This survey takes about 30 minutes to finish.
mechanism of action: No pharmaceutical intervention
last updated: December 23, 2019
start date: June 7, 2011
estimated completion: January 7, 2016
size / enrollment: 33
This study proposes to explore the role of family functioning in promoting adaptation in unaffected siblings of children with Duchenne muscular dystrophy (DMD). Although evidence suggests that family functioning may be a predictor of adaptation in caregivers of children with chronic illnesses, little research has been conducted on the relationships between aspects of family functioning and the adaptation of unaffected siblings. Evidence in the literature suggests that aspects of family functioning may play a key role in adaptation. Moreover, the role of DMD-specific communication in facilitating sibling adaptation has not yet been explored in the literature and further insight may be derived from exploring this relationship. The goals of this study are to better understand the relationship of family functioning with the adaptation of unaffected siblings, as well as to explore the timing, extent (depth and content), and the characteristics of initiation of discussion of parent-sibling communication around DMD.
Currently, some evidence exists to direct the creation of interventions that reinforce a family-centered approach to facilitate adaptation of family members to living with a child with a chronic health condition. Nevertheless, more insight is needed to understand how family processes affect individual adaptation, especially that of the unaffected sibling, in order to maximize the effectiveness of future interventions with this population.
- adaptation, behavior problems, self-concept, pro-social behavior
• Parent or caregiver of child with DMD and child without DMD
• Lives with child that does not have DMD
• 18 or older
• Reads/Writes English
• Sibling of child with DMD
• Lives in same household as individual with DMD
• 13-18 years of age
• Reads/Writes English
Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMDThis study will collect MRI from healthy...
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patie...Sarepta Therapeutics, Inc., a leader in ...
Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy (DMD) is a g...
A Phase IIa Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular DystrophyThis is a Phase 1, double-blind, placebo...
Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and CanadaDuchenne/Becker muscular dystrophy (DBMD...
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...
First targeted treatment success for Duchenne muscular dystrophyhttps://www.youtube.com/watch?v=tkxTn46_...
Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial...Sarepta Therapeutics, Inc., a commercia...
Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in D...Santhera Pharmaceuticals announces that ...